Timing of antibiotic therapy in the ICU
Open Access
- 15 October 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 25 (1), 1-10
- https://doi.org/10.1186/s13054-021-03787-z
Abstract
Severe or life threatening infections are common among patients in the intensive care unit (ICU). Most infections in the ICU are bacterial or fungal in origin and require antimicrobial therapy for clinical resolution. Antibiotics are the cornerstone of therapy for infected critically ill patients. However, antibiotics are often not optimally administered resulting in less favorable patient outcomes including greater mortality. The timing of antibiotics in patients with life threatening infections including sepsis and septic shock is now recognized as one of the most important determinants of survival for this population. Individuals who have a delay in the administration of antibiotic therapy for serious infections can have a doubling or more in their mortality. Additionally, the timing of an appropriate antibiotic regimen, one that is active against the offending pathogens based on in vitro susceptibility, also influences survival. Thus not only is early empiric antibiotic administration important but the selection of those agents is crucial as well. The duration of antibiotic infusions, especially for β-lactams, can also influence antibiotic efficacy by increasing antimicrobial drug exposure for the offending pathogen. However, due to mounting antibiotic resistance, aggressive antimicrobial de-escalation based on microbiology results is necessary to counterbalance the pressures of early broad-spectrum antibiotic therapy. In this review, we examine time related variables impacting antibiotic optimization as it relates to the treatment of life threatening infections in the ICU. In addition to highlighting the importance of antibiotic timing in the ICU we hope to provide an approach to antimicrobials that also minimizes the unnecessary use of these agents. Such approaches will increasingly be linked to advances in molecular microbiology testing and artificial intelligence/machine learning. Such advances should help identify patients needing empiric antibiotic therapy at an earlier time point as well as the specific antibiotics required in order to avoid unnecessary administration of broad-spectrum antibiotics.Keywords
This publication has 80 references indexed in Scilit:
- Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapyJournal of Critical Care, 2013
- Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysisCritical Care, 2013
- Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?Critical Care, 2013
- Factors influencing the implementation of antibiotic de-escalation and impact of this strategy in critically ill patientsCritical Care, 2013
- Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysisClinical Infectious Diseases, 2012
- A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumoniaCritical Care, 2012
- Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomesJournal of Antimicrobial Chemotherapy, 2011
- Predictors of 30-Day Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: Impact of Delayed Appropriate Antibiotic SelectionAntimicrobial Agents and Chemotherapy, 2007
- Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*Critical Care Medicine, 2006
- Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trialsThe Lancet Infectious Diseases, 2005